GLP-3R vs Semaglutide
GLP-3R and Semaglutide are both peptides studied in metabolic research and administered subcutaneously in research protocols. GLP-3R is investigated as a triple agonist at the GLP-1, GIP, and glucagon receptors, while Semaglutide is a long-acting GLP-1 receptor agonist with structural modifications that extend its half-life. The central mechanistic difference is breadth of receptor engagement: GLP-3R adds GIP and glucagon activity, the latter studied for a possible contribution to energy expenditure. GLP-3R has been studied for body weight reduction in obesity, glycemic control in type 2 diabetes, and liver fat. Semaglutide has been studied for weight loss, gastric emptying, satiety signaling, and pharmacokinetics, and a Semaglutide product, Wegovy, has been described as a weight loss drug.
Key differences
- 01
GLP-3R is studied at three receptors (GLP-1R, GIPR, and GCGR), whereas Semaglutide is studied at a single receptor, GLP-1R.
- 02
GLP-3R is at a late-clinical stage, with phase 2 trials and a published randomized phase 3 trial in type 2 diabetes but no reported regulatory approval, while a Semaglutide product, Wegovy, has been described in the literature as a weight loss drug for chronic weight management.
- 03
Mechanistic research on GLP-3R emphasizes a possible glucagon-linked energy expenditure effect, whereas Semaglutide research emphasizes slowed gastric emptying and an extended half-life.
- 04
GLP-3R research has extended to metabolic dysfunction-associated steatotic liver disease, obstructive sleep apnea, and knee osteoarthritis in trial designs, while Semaglutide has been examined in heart failure with preserved ejection fraction in observational research and in rodent studies of neural weight-regulation pathways.
- 05
Long-term human safety data for GLP-3R remain limited while registrational trials continue, whereas Semaglutide safety has been the subject of a dedicated published review, with optic neuropathy risk and lean mass effects specifically examined.
Side by side
Triple GLP/GIP/Glucagon — max fat loss, appetite control
GLP-1 research
Late clinical
Approved analog
Performance
Performance
Subcutaneous
Subcutaneous
Research protocols have used 500–4,000 mcg per administration, once weekly (morning, fasted), stepping up from 1 mg to 4 mg by week 9. Reported cycle: continuous until target weight loss; long-term non-weight-loss model: 1mg weekly.
Research protocols have used 250–2,000 mcg per administration, once weekly (morning, fasted), stepping up from 250 mcg to 2 mg by week 13. Reported cycle: continuous until target weight loss.
- Body weight reduction in adults with obesity
- Glycemic control in type 2 diabetes
- Liver fat in metabolic dysfunction-associated steatotic liver disease
- Obstructive sleep apnea and knee osteoarthritis in registrational trial designs
- Glucagon receptor contribution to energy expenditure
- Weight loss in obesity without diabetes
- Glucose-dependent insulin signaling via the GLP-1 receptor
- Gastric emptying and satiety signaling
- Distributed neural pathways of body weight regulation in rodents
- Heart failure with preserved ejection fraction in observational research
- Clinical pharmacokinetics and extended half-life
- Safety has been assessed in randomized phase 2 and phase 3 trials, though specific adverse events are not summarized on this page
- Long-term human safety data remain limited while registrational trials continue
- No regulatory approval for any indication has been reported
- Risk of nonarteritic anterior ischemic optic neuropathy has been examined in patients prescribed semaglutide
- Effects on lean mass have been reviewed across clinical trials
- Slowed gastric emptying is a studied mechanism of action
- Overall safety has been the subject of a dedicated published review
5 cited studies
5 cited studies
Studied ranges describe what published research protocols have used. They are not instructions or recommendations. Products are sold for research purposes only; each order ships with a protocol guide for the specific product.
Mechanism
GLP-3R
Research investigates GLP-3R across three receptors: GLP-1 and GIP for glucose-dependent insulin signaling and satiety, and glucagon for its association with energy expenditure.
Triple Agonism
Studied at three distinct metabolic receptors, the glucagon component being what separates it from dual agonists.
Energy Expenditure
Explored for whether glucagon receptor activity contributes an expenditure effect alongside appetite signaling.
Semaglutide
Research describes semaglutide as an incretin mimetic with structural modifications that extend its half-life, studied for both peripheral glucose handling and central appetite signaling.
Incretin Pathway
Studied at the GLP-1 receptor for glucose-dependent insulin release rather than unconditional stimulation.
Gastric Emptying
Explored for slowing the rate at which the stomach empties, associated with prolonged fullness.
